Schlaeger Thorsten M
Stem Cell Program, Boston Children's Hospital, Karp RB09213, 1 Blackfan Circle, Boston, MA, 02446, USA.
Adv Biochem Eng Biotechnol. 2018;163:1-21. doi: 10.1007/10_2017_29.
Traditional biomedical research and preclinical studies frequently rely on animal models and repeatedly draw on a relatively small set of human cell lines, such as HeLa, HEK293, HepG2, HL60, and PANC1 cells. However, animal models often fail to reproduce important clinical phenotypes and conventional cell lines only represent a small number of cell types or diseases, have very limited ethnic/genetic diversity, and either senesce quickly or carry potentially confounding immortalizing mutations. In recent years, human pluripotent stem cells have attracted a lot of attention, in part because these cells promise more precise modeling of human diseases. Expectations are also high that pluripotent stem cell technologies can deliver cell-based therapeutics for the cure of a wide range of degenerative and other diseases. This review focuses on episomal and Sendai viral reprogramming modalities, which are the most popular methods for generating transgene-free human induced pluripotent stem cells (hiPSCs) from easily accessible cell sources. Graphical Abstract.
传统的生物医学研究和临床前研究经常依赖动物模型,并反复使用相对较少的一组人类细胞系,如HeLa、HEK293、HepG2、HL60和PANC1细胞。然而,动物模型往往无法重现重要的临床表型,而传统细胞系仅代表少数细胞类型或疾病,其种族/遗传多样性非常有限,并且要么衰老迅速,要么携带可能产生混淆的永生化突变。近年来,人类多能干细胞引起了广泛关注,部分原因是这些细胞有望更精确地模拟人类疾病。人们也高度期望多能干细胞技术能够提供基于细胞的疗法,以治愈各种退行性疾病和其他疾病。本综述重点关注游离型和仙台病毒重编程方式,这是从易于获取的细胞来源生成无转基因人类诱导多能干细胞(hiPSC)的最常用方法。图形摘要。